Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Neuroone Medical Technologies (NMTC) Equity Ratio (2016 - 2025)

Neuroone Medical Technologies' Equity Ratio history spans 14 years, with the latest figure at 0.75 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 65.13% year-over-year to 0.75; the TTM value through Dec 2025 reached 0.75, up 65.13%, while the annual FY2025 figure was 0.66, 328.37% up from the prior year.
  • Equity Ratio reached 0.75 in Q4 2025 per NMTC's latest filing, up from 0.66 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.93 in Q1 2022 to a low of 0.15 in Q3 2024.
  • Average Equity Ratio over 5 years is 0.72, with a median of 0.76 recorded in 2023.
  • Peak YoY movement for Equity Ratio: soared 421.53% in 2021, then plummeted 80.17% in 2024.
  • A 5-year view of Equity Ratio shows it stood at 0.93 in 2021, then decreased by 8.85% to 0.85 in 2022, then fell by 10.3% to 0.76 in 2023, then tumbled by 40.44% to 0.45 in 2024, then soared by 65.13% to 0.75 in 2025.
  • Per Business Quant, the three most recent readings for NMTC's Equity Ratio are 0.75 (Q4 2025), 0.66 (Q3 2025), and 0.76 (Q2 2025).